Reflux sonography, as an alternative to micturating cystography (MCU), evaluates vesico-ureteral reflux (VUR), a common problem in children. Contrast enhanced pulse-inversion imaging shows best results. During the instillation of an ultrasound contrast agent into the bladder, (as for a conventional MCU) the lower ureters and renal pelves are scanned transabdominally as the bladder is filled to stimulate micturition.
Advantages for reflux sonography are a high sensitivity and the avoidance of X-rays. A disadvantage is the poorer depiction of the posterior urethra. However, for girls and for all follow-up studies, the ultrasound MCU has become standard in many pediatric ultrasound departments.

See also Urologic Ultrasound, Kidney Ultrasound, Ultrasound Safety, Ultrasound Imaging Modes.

Release burst imaging is a method based on the combination of multiple high frequency, broadband-detection pulses with a separate release burst. Release burst imaging is optimally suited to the characteristic of ultrasound contrast agents.
This method allows to improve both contrast sensitivity and imaging resolution. Imaging and transient enhanced scattering can be optimized separately. The release burst mode can be combined with a Doppler method to remove residual clutter signals from moving tissue.

See also Repetition Rate.

The second generation ultrasound contrast agents (UCA/USCA) are both sufficiently small and stable to pass into the systemic circulation, and these contrast media enhance the Doppler signal in various arteries after intravenous injection. Second generation agents have a short live, the contrast effect is over in a few minutes.

From Bracco Diagnostics Inc
SonoRx® is a gas-shadowing reduction agent, used in abdominal ultrasound to enhance the delineation of upper abdominal anatomy. This ultrasound contrast agents is designed to adsorb and displace stomach and bowel gas and should be taken after fasting for at least four hours. Ingestion orally of the simethicone-coated cellulose suspension over 15 minutes in dosages of 200 to 400 ml results in a homogeneous transmission of sound through the contrast-filled stomach.
Bristol-Myers Squibb, under license from ImaRx LLC;; marketed by Bracco Diagnostics Inc, Source: FDA approvals - 11/03/98

From Bayer Schering Pharma AG:
Sonovist® (sometimes found as Sonavist) is an investigational ultrasound contrast agent with a biodegradable synthetic capsule filled with sulphur hexafluoride. The biodegradable shell of Sonovist is so stable that it can be taken up by Kupffer cells of the reticuloendothelial system or accumulate in the sinusoids.
Therefore, Sonovist® has an additional hepato-splenic parenchymal phase following the blood pool phase, analog to the superparamagnetic iron oxide agents used in liver MRI. The microbubbles are stationary in this phase and generate no conventional Doppler signals. This tissue-specific phase has a variable duration and can be imaged by bubble specific imaging modes.